A 2026 single-center observational study reports preliminary evidence that botulinum toxin may be deliverable transdermally for sebum reduction in oily and acne-prone skin. Here’s what the early data shows and what providers should watch for.
The May 2026 aesthetic medicine update covers a neurotoxin pipeline producing genuinely new options and a patient population that is outgrowing the standard consult model. Providers who act on this month’s clinical and business signals — from GLP-1 protocol updates to the growing male aesthetic market — will be better positioned heading into the second half of 2026.
New randomized trial data confirms RF microneedling as a safe, effective standalone treatment for melasma in Fitzpatrick III-IV skin. Here’s what the evidence means for your protocols.
Physicians entering aesthetic medicine know how to diagnose. The consultation is different — it’s a goals-based conversation, not a problem-solving session. Here’s how to structure one that works.
hysicians entering aesthetic medicine know how to diagnose. The consultation is different — it’s a goals-based conversation, not a problem-solving session. Here’s how to structure one that works.
If you’ve been considering aesthetic medicine, 2026 may be the best entry window in years — a documented provider shortage, a wave of new patients, and a training path that’s more accessible than most providers realize. Here’s the realistic roadmap.
Not all regenerative aesthetics treatments are created equal — and in 2026, the evidence gap between them is wider than most product reps will tell you. Here’s an honest evidence rating for every major regenerative modality, plus a practical framework for talking to patients about what you can and can’t confidently offer.
Patients are arriving at aesthetic and weight management practices asking about NAD+. Here’s the clinical case for IV delivery, what the evidence actually shows, and how to build it into a practice already serving this patient.
63% of patients on GLP-1 medications are new to aesthetics — and they’re arriving with a distinct presentation that requires a different clinical and business approach. Here’s what GLP-1 aesthetic patients actually need from their provider, and how to build a practice model that serves them well.
Exosome therapy is showing up on practice menus faster than providers can vet the regulatory risk. Before you add it to your aesthetic practice, here’s what FDA enforcement in 2026 actually means for you.